Murchinson’s Viveon Health Acquisition Corp. Warrants to purchase one-half of a share of common stock at a price of $11.50 per whole share VHAQ.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-800,000
Closed -$71K 86
2022
Q3
$71K Hold
800,000
0.02% 52
2022
Q2
$36K Hold
800,000
0.01% 84
2022
Q1
$63K Hold
800,000
0.01% 95
2021
Q4
$173K Hold
800,000
0.02% 90
2021
Q3
$200K Hold
800,000
0.1% 61
2021
Q2
$281K Buy
+800,000
New +$288K 0.1% 80

Other funds holding VHAQ.WS

Murchinson's VHAQ.WS Position: Q4 2022 in Review

Murchinson sold out of Viveon Health Acquisition Corp. Warrants to purchase one-half of a share of common stock at a price of $11.50 per whole share (VHAQ.WS) in Q4 2022, closing a stake of 800,000 shares — an estimated $71K sold.

Murchinson first reported a position in VHAQ.WS in Q2 2021 and held it in 6 quarters. The position peaked at $281K in Q2 2021. 32 funds tracked by Wall St. Rank hold VHAQ.WS as of Q4 2022.

  • Murchinson reported no remaining Viveon Health Acquisition Corp. Warrants to purchase one-half of a share of common stock at a price of $11.50 per whole share position as of Q4 2022 after selling out during the quarter.
  • Murchinson sold 800,000 Viveon Health Acquisition Corp. Warrants to purchase one-half of a share of common stock at a price of $11.50 per whole share shares in Q4 2022, an estimated $71K.
  • Murchinson first reported a position in Viveon Health Acquisition Corp. Warrants to purchase one-half of a share of common stock at a price of $11.50 per whole share in Q2 2021 and held it in 6 quarters.
  • Murchinson's Viveon Health Acquisition Corp. Warrants to purchase one-half of a share of common stock at a price of $11.50 per whole share position peaked at $281K in Q2 2021.
  • 32 funds tracked by Wall St. Rank held Viveon Health Acquisition Corp. Warrants to purchase one-half of a share of common stock at a price of $11.50 per whole share as of Q4 2022.

Based on Murchinson's 13F filing for Q4 2022, filed 10 Feb 2023.